Overview

Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Status:
Recruiting
Trial end date:
2021-10-31
Target enrollment:
0
Participant gender:
All
Summary
This phase II trial studies the side effects and how well combination chemotherapy and nelarabine work in treating patients with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine, mercaptopurine, prednisone, pegaspargase, nelarabine, and venetoclax work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
GlaxoSmithKline
National Cancer Institute (NCI)
Treatments:
6-methoxypurine arabinoside
Asparaginase
BB 1101
Cortisone
Cyclophosphamide
Cytarabine
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Doxorubicin
Liposomal doxorubicin
Mercaptopurine
Methotrexate
Pegaspargase
Prednisone
Venetoclax
Vincristine
Criteria
Inclusion Criteria:

- Previously untreated T cell ALL including T cell lymphoblastic lymphoma; failure to
one induction course of chemotherapy are eligible; patients in CR after =< 2 courses
are also eligible

- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 3

- Serum bilirubin less than or equal to 2.0 mg/dL unless considered due to involvement
by tumor when an upper limit of 5.0 mg/dL is acceptable

- Serum glutamic oxaloacetic transaminase (SGOT) or serum glutamate pyruvate
transaminase (SGPT) less than or equal to 4 x upper limit of normal (ULN)

- Serum creatinine less than or equal to 2.0 mg/dL unless considered due to involvement
by tumor when an upper limit of 2.5 mg/dL is acceptable

Exclusion Criteria:

- Pregnant or nursing women